0RAD.LSE OSE Immunotherapeutics S.A.

Healthcare Oil, Gas & Consumable Fuels London Exchange
3.68 EUR
Close of Aug 22, 2026
1.85 5.88
Market cap
EUR 53.8M
P/E
-
P/B
-
ROE
-
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the fiscal year ending Dec 2021.

Is 0RAD.LSE undervalued?

Graham number

The Graham number of OSE Immunotherapeutics S.A. cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

OSE Immunotherapeutics S.A. fundamental analysis

No fundamental analysis for OSE Immunotherapeutics S.A. yet.

OSE Immunotherapeutics S.A. stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About OSE Immunotherapeutics S.A.

OSE Immunotherapeutics SA, a clinical-stage biotechnology company, develops immunotherapies in the areas of immune-oncology and immune-inflammation in France and internationally. The company's products include Tedopi that is in Phase III clinical trial for the treatment of non-small cell lung cancer, as well as in Phase II clinical trial to pancreatic and ovarian cancer; OSE-279, which is in a Phase I/II clinical trial in patients with advanced solid tumors or lymphomas; OSE…

Full company profile